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Smad3Runt-related transcription factor 2 (Runx2) plays an important role in bone formation and de novo synthesis
of proteins, including type 1 collagen. Runx2 has a potent effect on signaling of transforming growth factor
(TGF)-β and vice versa, implicating its signiﬁcant role in ﬁbrosis. Chronic renal failure comprises ﬁbrosis,
characterized as an increase in TGF-β signaling, and expression of α-smooth muscle actin (α-SMA), and ex-
tracellular matrix proteins. Here, we evaluated the role of Runx2 in ureteral obstruction (UO)-induced kidney
ﬁbrosis using mice whose Runx2 gene expression is genetically down-regulated. UO caused tubular atrophy
and dilation, expansion of interstitium, and increased expression of collagens and α-SMA with a concomitant
decrease in expression of Runx2. Deﬁciency of Runx2 gene (Runx2+/− mice) showed higher expression of
collagens and α-SMA in the kidney following UO compared to wild type (Runx2+/+) mice. UO-induced acti-
vation of TGF-β signaling was higher in the Runx2+/− kidney than Runx2+/+ kidney, suggesting an inhibito-
ry effect of Runx2 on TGF-β signaling in kidney ﬁbrosis. Besides, overexpression of the Runx2 gene using an
adenoviral vector in kidney tubule cells resulted in attenuated TGF-β-induced Smad3 phosphorylation and
expressions of α-SMA and collagen I. Furthermore, Runx2 gene deﬁcient mouse embryonic ﬁbroblasts in-
duced greater activation of Smad3 and expression of α-SMA in response to TGF-β. Collectively, Runx2
plays a protective role in UO-induced kidney ﬁbrosis by inhibition of TGF-β signaling, suggesting Runx2 as
a novel target for protection against ﬁbrosis-related diseases such as chronic renal failure.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Runt-related transcription factor 2 (Runx2) is known to play a
critical role in bone and tooth formation of which deﬁciency causes
skeletal and dental abnormalities [1–4]. Recently, the novel roles of
Runx2 have been elucidated. Runx2 plays important roles in various
cancers [5,6] and phenotypic modulation of vascular smooth muscle
cells (VSMC) [7], suggesting possible roles for other organs.
Studies have revealed tight correlation of Runx2 and TGF-β, the
most important factor in progression of ﬁbrosis [8]. TGF-β activates
transcription of Runx2, resulting in osteoblastic differentiation in a
pluripotent mesenchymal cell line C2C12 cell [9,10]. TGF-β also phos-
phorylates Runx2, which shows a cooperative effect on TGF-β-
stimulated collagenase 3 promoter activity in an osteoblastic cell
line [11]. Runx2 and TGF-β cooperate in induction of collagen 1 and
ﬁbronectin in C2C12 cells [12]. By contrast, a negative effect ofyungpook National University
u 700-422, Republic of Korea.
l rights reserved.TGF-β on Runx2 function and vice versa has also been reported.
TGF-β represses function of Runx2 through recruitment of class II
HDACs via Smad3 in differentiating osteoblasts [8] and through
ALK5/Smad3 signaling in human dental pulp cells [13]. Runx2/
Smad3 complex negatively regulates TGF-β, resulting in inhibition
of gene expression of connective tissue growth factor (CTGF) in
VSMC [7]. Up-regulation of TGF-β-induced CTGF plays a critical role
in kidney ﬁbrosis [14]. In addition, Runx2 also regulates expression
of other ﬁbrosis-related genes. Runx2 induces expression of the MMP9
and MMP13 genes, which act as collagenases [15]. Runx2 suppresses
expression of type I collagen in osteoblastic and nonosteoblastic
cell lines [16] and myocardin-induced SMC genes such as α-SMA in
VSMC [17]. These results suggest the potent role of Runx2 in ﬁbrosis.
However, the role of Runx2 in organ ﬁbrosis, including kidney ﬁbrosis,
is unknown.
Kidney ﬁbrosis is the hallmark of progressive renal disease and a
common pathway to end stage renal disease. The experimental
model of ureteral obstruction (UO) induces progressive kidney ﬁbro-
sis. UO results in tubular cell injury and death, epithelial–mesenchymal
transdifferentiation (EMT), elevation of proinﬂammatory mediators
and cytokines, increased macrophage inﬁltration, proliferation of inter-
stitial ﬁbroblasts with myoﬁbroblast transdifferentiation, leading to
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and impairment of renal function. [18–20].
In this study, we investigated the role of Runx2 in UO-induced
kidney ﬁbrosis using Runx2 heterozygous mice (Runx2+/−) and in
TGF-β-induced EMT using a kidney epithelial cell line an MDCK cell
culture system.
2. Materials and methods
2.1. Animal preparation
All animal experiments were conducted in accordance with guide-
lines of the institutional Animal Care and Use Committee at Kyungpook
National University. Eight-week-old male wild type (Runx2+/+) or
C-terminus truncated Runx2 heterozygous (Runx2+/−) mice were
used. Runx2+/− mice were established as previously described [2].
Genotyping of Runx2+/− mice was performed as previously described
[21]. Mice were permitted free access to water and standard mouse
chow. Each animal group included at least four mice. Sham or UO was
performed as previously described [22]. Brieﬂy,micewere anesthetized
with pentobarbital sodium (60 mg/kg body wt., i.p., Sigma, St. Louis,
MO). The left kidney was exposed through the site of the left ﬂank inci-
sion. The left ureter was obstructed completely near the renal pelvis
using 6-0 nylon. Sham-operated mice underwent the same surgical
procedure, except for ureter ligation. Kidneys were either perfusion-
ﬁxed in PLP (4% paraformaldehyde, 75 mM L-lysine, 10 mM sodium
periodate) solution for histological studies, or snap-frozen in liquid ni-
trogen for western blot analysis.
2.2. Western blot analysis
Protein samples were prepared and western blot analyses were
performed as previously described [23]. Protein samples were
electrophoresed and subjected to immunoblotting with antibodies
against Runx2 (Santa Cruz Biotechnology, Santa Cruz, CA), collagen
III (MyBioSource, Inc., San Diego, CA), α-smooth muscle actin
(α-SMA, Sigma, St. Louis, MO), transforming growth factor-β1
(Santa Cruz Biotechnology, Santa Cruz, CA), phospho-Smad3 (cell sig-
naling Technology, Inc., Danvers, MA), Ly6G (eBioscience, San Diego,
CA), CD68 (Serotec, Raleigh, NC), and GAPDH (Novus Biologicals,
LLC, Littleton, CO). Horseradish peroxidase-conjugated secondary an-
tibodies (DakoCytomation Inc., Carpinteria, CA) were applied, and
immunoblots were visualized using chemiluminescence reagent
(Thermo Scientiﬁc, Rockford, IL). Densities of immunoblots were
quantiﬁed using image analysis software ImageJ (NIH).
2.3. Collagen deposition
PLP-ﬁxed kidneys were washed with PBS three times for 5 mi-
nutes each time, embedded in parafﬁn, and cut into 2-μm thick
sections using a microtome (RM2165, Leica, Bensheim, Germany).
Parafﬁn-sections were stained with Masson's trichrome and immuno-
ﬂuorescence staining for collagen type III using anti-collagen III anti-
body (Abcam, Cambridge, UK) and Texas Red-conjugated anti-rabbit
secondary antibody (Vector Laboratories Inc., Burlingame, CA) as
described previously [24,25]. Micrographic pictures of images for
Masson's trichrome and immunoﬂuorescence staining from 4 indepen-
dentmicewere taken using a NikonMicrophot-Fx (Nikon Inc., Melville,
NY) for bright ﬁeld and ﬂuorescence, respectively. Collagen deposition
was analyzed in 10 random ﬁelds (0.23 mm2/ﬁeld) using LabWorks
4.5 software (Ultra-Violet Products, Cambridge, UK).
2.4. MDCK cell culture and Runx2 overexpression
The 8–10 passages of Madin–Darby Canine Kidney cells (MDCK,
American Type Culture Collection, Manassas, VA) cultured in DMEMwith 5% FBS (Mediatech Inc., Manassas, VA) with 100 u/ml of strepto-
mycin/penicillin (S/P) (WelGENE Inc., Daegu, Korea) were used. For
overexpression of Runx2, adenovirus carrying 400 MOI of LacZ or
Runx2 was transfected to 10–20% conﬂuent MDCK cells for 5 h in
FBS and S/P free DMEM; the medium was then changed to 5% FBS
with S/P. When cells reached 50–60% conﬂuency, we changed the
medium to DMEM with 1% FBS and S/P. The cells were treated with
5 ng/ml of TGF-β for 48 h. Cells were rinsed with cold PBS and then
lysed in the same lysis buffer, and subjected to western blot analyses,
as described in Section 2.2.
2.5. Immunoﬂuorescence staining
Parafﬁn-embedded tissue sections were prepared as described
in Section 2.3. Immunoﬂuorescence staining for F4/80 was per-
formed using anti-F4/80 antibody (Serotec, Raleigh, NC) and Texas
Red-conjugated anti-mouse secondary antibody (Vector Laborato-
ries Inc., Burlingame, CA) and pictures were taken as described in
Section 2.3.
2.6. Cell culture of primary mouse embryonic ﬁbroblasts (MEF)
Male and female Runx2+/− mice were mated and littermates
were obtained at gestation day 13. MEFs were collected from day
12.5 mouse embryos and cultured in DMEM supplemented with
15% FBS and 100 units of S/P per milliliter. Cells were used at passages
3–8. Genomic PCR, for genotyping of every cultured cell, was performed
using Taq DNA polymerase (Fermentas, Glen Burnie, Maryland). When
cells reached 50–60% conﬂuency, culture medium was changed to
DMEM with 1% FBS and S/P. The cells were treated with 5 ng/ml of
TGF-β for 48 h and after treatment, were rinsed with cold PBS, lysed
in the lysis buffer, and subjected to Western blot analyses, as described
in Section 2.2.
2.7. Periodic acid Schiff (PAS) staining
Parafﬁn-embedded tissue sections were prepared as described in
Section 2.3. PAS staining was carried out as described previously
[24]. Micrographic pictures of kidney from 4 independent mice
were taken using a Nikon Microphot-Fx (Nikon Inc., Melville, NY).
2.8. Semi-quantitative reverse transcription (RT)-PCR
RNA was extracted using RNeasy kit (Qiagen, Valencia, CA)
followed by cDNA synthesis using Revert Aid First Strand cDNA Syn-
thesis Kit (Fermentas, Glen Burnie, Maryland). PCR was performed
using Taq DNA polymerase (Fermentas, Glen Burnie, Maryland). PCR
primer sequences used were 5′CACTATCCAGCCACCTTTACTT3′ and
5′GATCCTGACGAAGTGCCATAG3′ for Runx2, 5′GTGACATCGACATCAG
GAAAGA3′ and 5′GATCCACATCTGCTGGAAGG3′ for α-SMA, 5′ACGGA
TTCCAGTTCGAGTATG3′ and 5′GTAGGTGACACTGTAGGTGAAG3′ for
collagen I, 5′AGTCAAGGCTGAGAACGGGAAACT3′ and 5′TCCACAACA
TACTCAGCACCAGCA3′ for GAPDH.
2.9. Transient transfection and luciferase assay
Transfection was performed with DharmaFECT (Thermo Scientiﬁc,
Rockford, IL) according to the manufacturer's instructions. Cells were
seeded in triplicate in 6-well plate at a density of 5 × 105 cells/well
and were transiently cotransfected with CAGA-luc, psvβ-gal and
Runx2. Twenty-four hours after transfection, medium was changed
to DMEM with 1% FBS. The cells were treated with 5 ng/ml of TGF-β
for 16 h and then harvested with Luciferase Cell Culture Lysis reagent
(Promega, Madison, WI). Luciferase activities were measured using
the luciferase assay system (Promega, Madison, WI) according to
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β-galactosidase activities.
2.10. Statistics
Results were expressed as the mean ± SE. Statistical differences
among groups were calculated using ANOVA and statistical differ-
ences between the groups were evaluated with an analysis of
variance using Student's t-test. Differences between groups were con-
sidered statistically signiﬁcant with a P value of b0.05.
3. Result
3.1. Unilateral ureteral obstruction results in decreased expression of
Runx2 in the obstructed kidney
To examine the association of Runx2 with UO-induced renal inju-
ry, we performed western blot analysis for determination of Runx2
protein expression in the obstructed kidney. First, we conﬁrmed
that Runx2 is constitutively expressed in the kidney, and was lower
in Runx2+/− mice, compared with Runx2+/+ mice (Fig. 1). Expres-
sion of Runx2 was reduced by UO in both Runx2+/+ and Runx2+/−
mice, suggesting regulation of Runx2 by UO-induced signals, and an
association with UO-induced kidney injury. Runx2 expression after
UO was still signiﬁcantly lower in Runx2+/− mice, compared with
Runx2+/+ mice (Fig. 1).
3.2. Reduction of the Runx2 gene enhances UO-induced kidney ﬁbrosis
To examine the role of Runx2 in UO-induced kidney ﬁbrosis, we
determined ﬁbrotic changes of kidneys in Runx2+/+ and Runx2+/−
mice. UO resulted in upregulation of collagen I, collagen III, and
α-SMA, demonstrating successful induction of ﬁbrosis. UO-induced
expression of collagen I, collagen III, and α-SMA was signiﬁcantly
greater in Runx2+/− mice, compared with Runx2+/+ mice (Fig. 2a
to d). In accordance with immunoblotting results, deposition ofSham
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Fig. 1. Ureteral obstruction decreased Runx2 expression in the obstructed kidney.
(a) Representative immunoblot with antibodies for Runx2 and GAPDH at 5 days after
sham operation or ureteral obstruction. (b) Protein levels of Runx2 were normalized
with GAPDH. Data are presented as mean ± SE (n = 4). UO, ureteral obstruction.collagen III as determined by immunoﬂuorescence staining for colla-
gen type III (Fig. 2e) and Masson's trichrome (Fig. 2f and g) in the
interstitium of obstructed kidneys were greater in Runx2+/− mice,
compared with Runx2+/+ mice, indicating that Runx2 plays a protec-
tive role in UO-induced kidney ﬁbrosis.
3.3. Reduction of the Runx2 gene enhances UO-induced kidney
inﬂammation
To examine whether increased ﬁbrotic change in Runx2+/− mice
is associated with the increased inﬂammatory response, we deter-
mined the level of Ly6G, a marker for granulocyte inﬁltration, and
CD68, a marker of monocyte/macrophage. UO resulted in an increase
in expression levels of Ly6G and CD68, in both types of mice. The
levels of Ly6G and CD68 were greater in Runx2+/− mice than in
Runx2+/+ mice (Fig. 3a to c). Numbers of interstitial cells which con-
tain inﬁltrated inﬂammatory cells [25] were also greater in Runx2+/−
mice than in Runx2+/+ mice (Fig. 3d to f). These results indicate that
Runx2 plays an inhibitory role in UO-induced kidney inﬂammation.
3.4. Enhanced kidney ﬁbrosis in Runx2+/− mice was through increased
TGF-β pathway
To examine whether increased ﬁbrotic change in Runx2+/− mice
is associated with the increase of TGF-β signaling, we determined
the level of activated TGF-β signaling via phosphorylation of Smad3.
UO increased both TGF-β and phosphorylated Smad3 levels in both
types of mice. However, the levels of activated TGF-β and phosphor-
ylated Smad3 were greater in Runx2+/− mice than in Runx2+/+
mice (Fig. 4a to c).
3.5. Overexpression of the Runx2 gene ameliorated TGF-β-induced
transdifferentiation of kidney tubular cells into myoﬁbroblasts
Results generated in in vivo studies (Figs. 1–4) indicate that re-
duction of the Runx2 gene enhances progression of ﬁbrosis following
UO through up-regulation of TGF-β signaling pathway, suggesting
that up-regulation of Runx2 may attenuate ﬁbrosis via inhibition of
TGF-β signaling. Therefore, we tested that over-expression of Runx2
results in reduction of TGF-β-induced epithelial–mesenchymal tran-
sition (EMT) in cultured kidney tubular epithelial cells. MDCK cells
were infected with adenovirus expressing Runx2 (Ad-Runx2) or
LacZ (Ad-LacZ), and then treated with TGF-β, a well-known inducer
of ﬁbrotic changes in tubular epithelial cells. The 200 and 400 MOI
of Ad-Runx2 effectively increased levels of Runx2 protein in the
MDCK cells, however, the Ad-LacZ did not (Fig. 5a). TGF-β treatment
decreased Runx2 levels in Ad-Runx2-infected cells, but not in
Ad-LacZ-infected cells (Fig. 5b and c). TGF-β-induced phosphoryla-
tion of Smad3 was signiﬁcantly increased in Ad-LacZ-infected cells
compared to Ad-Runx2-infected cells (Fig. 5b and d), indicating that
Runx2 inhibits the TGF-β/Smad3 signaling pathway. Basal and
TGF-β-induced protein expressions of α-SMA and collagen I, markers
of myoﬁbroblasts, were greater in Ad-LacZ-infected cells compared to
Ad-Runx2-infected cells (Fig. 5b, e and f). TGF-β-induced mRNA
levels of Runx2, α-SMA, and collagen I showed a similar patterns
with levels of proteins (Fig. 6a to d). These results indicate that
Runx2 inhibits TGF-β-induced ﬁbrosis in kidney.
3.6. Overexpression of Runx2 gene ameliorated TGF-β-induced CAGA re-
porter activity
In order to conﬁrm the inhibitory role of Runx2 in TGF-β signaling,
we examined reporter activity of CAGA, a TGF-β response element
[26]. TGF-β treatment greatly increased CAGA reporter activity in
both control and Runx2-overexpressed MDCK cells. However,
overexpression of Runx2 gene ameliorated CAGA reporter activity,
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Runx2 in TGF-β signaling.
3.7. Ablation of Runx2 gene function accelerated TGF-β-induced trans-
formation of mouse embryonic ﬁbroblast (MEF) cells into myoﬁbroblasts
In order to conﬁrm the inhibitory role of Runx2 in TGF-β-induced
ﬁbrotic progress, we investigated TGF-β-induced transformation
of embryonic ﬁbroblast (MEF) into myoﬁbroblast. TGF-β increased
phosphorylation of Smad3 and expression of α-SMA in both
Runx2+/+ and Runx2−/− MEF cells. However, TGF-β-induced phos-
phorylation of Smad3 in MEF obtained from Runx2−/− embryo was
greater than in MEF from Runx2+/+ embryo (Fig. 8a and b). Expres-
sion of α-SMA in MEF obtained from Runx2−/− embryo was greater
than in MEF from Runx2+/+ embryo (Fig. 8a and c), conﬁrming the
inhibitory role of Runx2 gene in TGF-β-induced ﬁbrosis.
4. Discussion
In this study, we demonstrate for the ﬁrst time that Runx2, a tran-
scription factor regulating bone formation, protects kidney againstUO-induced ﬁbrosis. This conclusion is supported by several lines
of evidence. 1) UO down-regulates Runx2 expression in the kidney.
2) UO-induced ﬁbrotic changes of kidney in Runx2+/− mice are
greater than those in Runx2+/+ mice. 3) UO-induced inﬁltration of
inﬂammatory cells in the kidney of Runx2+/− mice is greater than
that of Runx2+/+ mice. 4) UO-induced TGF-β signaling in kidney of
Runx2+/−mice is greater than that of Runx2+/+mice. 5)Overexpression
of the Runx2 gene inhibited TGF-β-induced transdifferentiation of kidney
tubule cells into myoﬁbroblasts. 6) Functional Runx2 deﬁcient MEF cells
induced greater activation of Smad3 and expression ofα-SMA than con-
trol cells did. These results suggest that the Runx2 gene would be a good
target for development of novel treatments for ﬁbrotic kidney diseases.
In addition to its well-known role in bone formation, a novel role
for Runx2 in vascular pathophysiology, such as vascular calciﬁcation,
has recently been reported [27,28]. Vascular calciﬁcation is a common
complication in chronic kidney disease (CKD), which is one of the
leading causes of death in patients with end stage renal disease
(ESRD) [29]. It suggests a possible role for Runx2 in kidney ﬁbrosis.
Therefore, we investigated the role of Runx2 in UO-induced kidney ﬁ-
brosis. UO is a well-established animal model for kidney ﬁbrosis.
Lines of evidence suggest that the rodent model of UO is reﬂective
of human renal disease processes [18].
Blockage of urine ﬂow by UO induces accumulation of urine in the
pelvis and a retrograde increase in interstitial pressure causing in-
creased hydrostatic pressure into the tubules and tubular distension,
resulting in damage to epithelial tubular cells. This is followed by in-
terstitial inﬂammatory response, such as inﬂammatory cell inﬁltra-
tion and myoﬁbroblast accumulation in the interstitium. Damaged
tubular cells, interstitial inﬂammatory cells, and myoﬁbroblasts pro-
duce cytokines and growth factors, such as TGF-β, which exacerbate
inﬂammation, resulting in further tubular cell apoptosis and tubular
atrophy, and accumulation of extracellular matrix (ECM) such as col-
lagens [25,30,31]. Consistent with these reports, in the current study,
UO induced activation of TGF-β, inﬁltration of leukocytes and macro-
phages, and ﬁbrosis, and these phenomena were greater in Runx2+/−
mice than in Runx2+/+ mice, indicating an anti-inﬂammatory and
anti-ﬁbrotic role of Runx2 through inhibition of the TGF-β signaling
pathway. However, unexpectedly, inﬂammatory response of VSMC
according to the level of Runx2 was opposite to that in the obstructed
kidney. Expression of Runx2 showed positive correlation with in-
ﬂammation, resulting in calciﬁcation of VSMC [28,32]. Furthermore,
unlike the results that increased oxidative stress was associated
with up-regulated Runx2 expression in the VSMC [28,32], UO rather
decreased Runx2 expression in the obstructed kidney in our results.
We speculate that this ﬁnding reﬂects differential expressional
regulation and the effect of the Runx2 gene in different tissues
and signals.
It is likely that positive feedback of TGF-β activation and inﬂam-
mation induced further kidney ﬁbrosis, resulting in increased EMT
and myoﬁbroblast proliferation, which were evidenced by increased
expression and deposition of α-SMA, collagen I, and collagen III in
Runx2+/− mice, compared to Runx2+/+ mice. This indicates that
Runx2 plays as a negative regulator of progression of ﬁbrosis induced
by UO through inhibition of TGF-β signaling. TGF-β is a key mediator
in development of renal ﬁbrosis and inﬂammation [33]. Runx2 and
TGF-β signal are tightly associated in a cell type dependent manner.
Positive cooperation of Runx2 with TGF-β in induction of osteoblast-
speciﬁc gene expression in a pluripotent mesenchymal precursor cell
line, C2C12 cells [12], or negative cooperation with TGF-β in inhibition
of expression of connective tissue growth factor (CTGF) in VSMC has
been reported [7]. CTGF is one of the factors mediating ﬁbrogenic activ-
ity of TGF-β; its reduction by antisense treatment resulted in ameliora-
tion of renal tubulointerstitial ﬁbrosis induced by UO [14]. Thus, it
appears that Runx2 plays a positive role in osteogenic change but an in-
hibitory role in ﬁbrotic change. In our study, Runx2 showed an inhibito-
ry role in UO-induced TGF-β signaling resulting in reduced production
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in suppression of type 1 collagen also supports our data.a LacZ
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Runx2+/− mice than in Runx2+/+ mice. Another factor contributing
to kidney ﬁbrosis EMT is also thought to be driven by TGF-β [34]. To
conﬁrm the inhibitory role of Runx2 in TGF-β-induced EMT, we ex-
amined TGF-β-induced expression of α-SMA in cultured renal tubular
cells, of which Runx2 expression was increased over 3 times by infec-
tion of adenovirus delivering the Runx2 gene. In the present study,
TGF-β treatment decreased Runx2 expression in the Runx2 over-
expressed cells, but not in the LacZ-infected cells. Although there
was a TGF-β-induced decrease of Runx2 in Runx2-overexpressed
cells (but its level was still higher then TGF-β-treated LacZ cells),
the overexpression of Runx2 almost completely prevented the TGF-
β-induced increases of α-SMA and type I collagen expression without
complete inhibition of Smad3 activation (TGF-β-induced phosphory-
lation of Smad3 was mostly, but not completely, abolished in Runx2
overexpressed cells). These data suggest that Runx2 may regulate
the progression of ﬁbrosis via not only Smad3 but also other factors.
However, results achieved by experiments using Runx2 gene deﬁ-
cient MEF cells and CAGA reporter gene clearly show that Runx2
plays the role of a critical regulator in the progression of kidney ﬁbro-
sis via TGF-β/Smad3 signal, at least, in part.
In conclusion, UO resulted in decreased expression of Runx2,
resulting in reversal of the inhibitory effect on TGF-β activation,
TGF-β-induced EMT, ECM production, and kidney ﬁbrosis according-
ly. We propose that targeting Runx2 is a novel and effective strategy
for treatment and prevention of kidney ﬁbrosis.Acknowledgement
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